




RealRate

PHARMACEUTICAL 2021

RAPT Therapeutics Inc.
Rank 218 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2021

RAPT Therapeutics Inc. Rank 218 of 409



The relative strengths and weaknesses of RAPT Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RAPT Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 154% points. The greatest weakness of RAPT Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 141% points.

The company's Economic Capital Ratio, given in the ranking table, is -150%, being 204% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	115,598
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,742
Liabilities, Non-Current	0
Other Assets	389
Other Compr. Net Income	-197
Other Expenses	990
Other Liabilities	3,048
Other Net Income	1,312
Property and Equipment	2,982
Research and Development	45,485
Revenues	5,042
Selling, General and Administrative Expense	12,771

Output Variable	Value in 1000 USD
Assets	118,969
Liabilities	14,790
Expenses	59,246
Stockholders Equity	104,179
Net Income	-52,892
Comprehensive Net Income	-52,990
Economic Capital Ratio	-150%

